Pages
- Adcirca®
- Adcirca® FAQ
- Aironite®
- Ambrisentan
- BiPAP / CPAP
- Bosentan
- Calcium Channel Blockers
- Coumadin®
- Digitalis
- Diuretics
- Endothelin Receptor Antagonists
- Epoprostenol for Injection
- Epoprostenol sodium
- Flolan®
- Iloprost
- Inhaled Treprostinil
- INOmax®
- Jantoven®
- Letairis®
- Marfarin®
- Nitric Oxide
- Nitrite
- Other Drugs and Treatments
- Oxygen
- Phosphodiesterase type-5 Inhibitor
- Prostacyclin
- PTE
- Remodulin®
- Revatio®
- Sildenafil Citrate
- Sitaxsentan Sodium
- Tadalafil
- Thelin®
- Tracleer®
- Tracleer® FAQ
- Transplant
- Treprostinil
- Tyvaso®
- Under FDA Review
- Veletri®
- Ventavis®
- Viagra®
- Volibris®
- Warfarin
Prostacyclin
Prostaglandin is a steroid that is produced naturally in the body of a normally healthy person. It causes blood vessels in the lungs to relax and allow blood to flow through them easily. People with pulmonary hypertension do not produce enough prostaglandin, causing the blood vessels in the lungs to be somewhat constricted. Prostacyclin, also known as epoprostenol, is a synthetic substance that is administered to remedy this deficiency in some PH patients. Prostacyclin therapy was initially used as a bridge to lung transplantation but has emerged as an alternative to transplantation in numerous patients in recent years.
Although research continues on other forms of prostacyclin, it is currently available in these forms:
For Additional Information Visit:
- Pulmonary Hypertension, Primary, Ronald J Oudiz, MD, Director of Pulmonary Hypertension, Associate Professor, Department of Medicine, Division of Cardiology, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA
Page Reviewed/Edited: November 2010
In The News
- November 16, 2011
- CHEST: Oral Prostanoid Shows Promise in PAH
- September 17, 2011
- Management of PAH: When and How to Use IV Agents
- January 23, 2011
- Differential Response to Intravenous Prostacyclin Analog Therapy in Patients with PAH
- December 13, 2010
- Arena Pharma initiates pulmonary hypertension drug clinical study of APD811
- December 10, 2010
- Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
- May 17, 2010
Actelion announces presentation of positive Phase II results with selexipag in patients with pulmonary arterial hypertension- April 27, 2010
Standard PAH therapy improves long term survival in CTEPH patients.- April 26, 2010
- New Epoprostenol formulation availlable (no cooling)
- November 30, 2009
- Serious Errors in Prostacyclin Administration Not Uncommon
- November 4, 2009
- Study Finds Life-Threatening Risks from Medication Errors in Hospitals Treating Pulmonary Hypertension Patients

.jpg)